Home › Compare › PCRRF vs ABBV
PCRRF yields 2.89% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, PCRRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PCRRF + ABBV for your $10,000?
Pasco Corporation engages in the acquisition, analysis, and provision of geospatial information in Japan and internationally. It offers spaceborne services that handle data from the commercial earth observation satellites launched worldwide; and airborne surveying services, such as aerial photography, aerial laser, thermal sensor, hyperspectral sensor, oblique aerial photography, and airborne IFSAR surveying, as well as portable aerial photography and locator systems. The company also provides vehicle/ground surveying services, including road condition laser, road condition, global positioning system, total station, precision, and terrestrial laser surveying, as well as ground based InSAR and radar; and water area surveying services comprising bathymetry and seabed exploration. In addition, it offers geographic information system (GIS) cloud services for the municipalities and central government, cloud-based regional analysis and marketing services for the private companies, and reassurance with disaster prevention systems; customization and GIS application development; and geospatial information consulting services, including regional strategy analysis, disaster prevention and mitigation consultant, road and bridge design, water supply and sewage facility management, dam and port management, rivers and erosion control, mapping solutions, and maintenance services. The company was formerly known as Pacific Koku Sokuryo Co., Ltd. and changed its name to Pasco Corporation in 1983. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Pasco Corporation is a subsidiary of Secom Co., Ltd.
Full PCRRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.